Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDNF and QEEG as Biomarkers of Response to (Es)Citalopram in MDD
NCT00361218Phase 3Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2005
- Primary completion
- Dec 2008
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of Escitalopram oxalate oral solution and citalopram in major depressive disorder (MDD), sponsored by Massachusetts General Hospital. Primary endpoints: Serum Brain-derived Neurotrophic Factor Levels at 8 weeks and Quantitative Electroencephalogram Parameters at 8 weeks. Started Oct 2005; status: completed.
02
Drugs
Escitalopram oxalate oral solutioncitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00361218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361218.